Brief: Cyxone: Study Confirms Drug Candidate T20K's Safety And Tolerability In Humans

Cyxone AB

02/08/2019 09:43

Aug 2 (Reuters) - Cyxone AB  CYXO.ST :
    * SAID ON THURSDAY CLINICAL PHASE I TRIAL WITH DRUG
CANDIDATE T20K
SUCCESSFULLY ACHIEVED ITS PURPOSE OF CONFIRMING T20K’S SAFETY
AND TOLERABILITY IN HUMANS
    * THERE WERE NO REPORTS OF SERIOUS ADVERSE EVENTS IN THIS
INFUSION
STUDY
    * T20K, WHICH IS UNDER DEVELOPMENT FOR THE TREATMENT OF
MULTIPLE
SCLEROSIS, WILL AS A NEXT STEP IN THE DEVELOPMENT PROGRAM BE
PREPARED AS AN ORAL FORMULATION FOLLOWED BY A FURTHER CLINICAL
PHASE I STUDY

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nWkr4ysYjL
    
 Further company coverage:  CYXO.ST  
   


 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920))